Evista Does Not Prevent Heart Attacks
Eli Lilly osteoporosis drug, Evista aka raloxifene, appears to reduce the risk of invasive breast cancer but does not have any protective effects on the heart. There were some signs in previous clinical trials that Evista was capable of reducing LDL cholesterol, but a recent study of 10,000 women did not show the same effects.
There was no difference in overall death or cardiovascular death among women who took Evista compared with those who took a placebo. The company said there was an increase in stroke mortality, although the overall incidence was low.
Sometimes it seems to me that testing to see the various effects new pharmaceutical drugs may have is like a fishing expedition. First, Evista was designed for osteoporosis then someone noticed that it may reduce the risk of heart attacks and even breast cancer. So they begin to pursue these other lucrative uses as well. Medical science does tend to be trial and error but I’m not sure I would want to enroll in these experimental studies.
Reuters, April 12, 2006
Tags: cardiovascular-disease, cholesterol, cvd, disease, evista, health, heart, heart-attacks, heart-disease, ldl, raloxifene, womenRelated Stories
POSTED IN: Hearty Research
0 opinions for Evista Does Not Prevent Heart Attacks
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: